TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04619667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula (HFNC)
Description: HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula (HFNC)
Description: HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity
Study: NCT03682406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS-G
Description: Group-based suicide-specific intervention based upon the Collaborative Assessment and Management of Suicidality.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CAMS-G
Description: Group-based suicide-specific intervention based upon the Collaborative Assessment and Management of Suicidality.
Study: NCT04619667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet
Study: NCT01513863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Topical Gel 1%
Description: Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
Study: NCT04149171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC),administration of Crystalloids and TXA.
Description: The treating physician must have evaluated the patient's eligibility and approved the patient's enrolment in the trial prior to blood samples extraction and RBC, TXA and Fibrinogen Concentrate administration. The experimental and control arms will be determined according to the medical emergency system units with RBC, TXA and Fibrinogen Concentrate administration capacity which will be the H2 helicopter unit ,fast intervention vehicle and G409 ambulance (Advanced Life Support). The medical emergency system units are activated according current protocols based on distance, severity and weather conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: standard treatment based on crystalloid fluid and tranexamic acid (TXA)
Study: NCT02812238

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR)
Description: NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR)
Description: NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
Study: NCT03672851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD123 CAR-T treatment
Description: Patients receive fludarabine phosphate(300 mg/m\^2) and cyclophosphamide (30 mg/m\^2) IV on days -5 to -3, and then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the side-effects occured). The total dose of CAR-T cells used in dose-escalation study is 0.5x10\^6- 2.0x10\^6 CAR-T cells/kg.
Study: NCT00124969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg
Study: NCT03409952

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LaseMD and DUAL 1927nm Laser
Description: Laser treatment of benign pigmented lesion based on photothermolysis whereby the target molecule, the chromophore, absorbs a delivered wavelength of light over a period of time to damage the target while limiting collateral damage to adjacent structures, leading to pigmentary clearance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LaseMD
Description: Laser treatment of benign pigmented lesion using optimized treatment settings.
Study: NCT00776542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline 100mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline 100mg Tablets
Study: NCT02409641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclopentolatehydrochloride 0,5% eye drops
Description: 1 drop in study eye
Study: NCT02110485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Activation Tool
Description: An interactive tablet based tool designed to (1) teach patient activation strategies; (2) provide evidence-based information about a health condition, (3) help patient/caregiver dyads recognize and clarify their own values, and (4) provide guidance in decision making and communication among those involved with the decision.
Study: NCT01513863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Topical Gel 1% (Metrogel)
Description: Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
Study: NCT04808713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment
Description: The treatment is a therapist-assisted self-help online cognitive-behaviour therapy focusing on post-traumatic stress, sleep and mood. It includes 12 sessions of evidence-based psychotherapeutic components, such as psychoeducation about PTSD, sleep and depression; prolonged exposure to avoided situations and memories; sleep management strategies (restriction of time in bed, stimulus control, sleep hygiene education); behavioural activation; relaxation and mindfulness exercises; problem-solving strategies; and cognitive restructuring. A small portion of material was unlocked each week, and access to one module was accessible after the completion of a previous one. Supervised graduate psychology students provided brief regular weekly contacts for 12 weeks by video chat or phone, according to the participant's preference. Access to the online material was unlimited in time.
Study: NCT01191515

Intervention type: DEVICE
Intervention: Monofocal Intraocular Lenses
Description: Monofocal Intraocular Lenses

Intervention type: DEVICE
Intervention: Monofocal Intraocular Lenses
Description: Monofocal Intraocular Lenses
Study: NCT03123900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The structured physical activity plan consists of a walking program with an initial progressive phase (first week: 30 minutes/session and second week: 45 minutes/session, with a Borg scale of perceived exertion between 9 and 10) and an improvement and maintenance phase (10 weeks, 45 minutes/session with a Borg scale of perceived exertion between 11 and 14).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: We use a computerized cognitive training tele-medicine tool, designed by the Guttmann Institute: Guttmann Neuro Personal Trainer (PREVIRNET). Sessions will consist in activities of attention, memory and executive functions, also put in place progressively and parallel to the physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined training
Description: Subjects included in this group receive both types of intervention.
Study: NCT04671563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate 300 MG
Description: One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate 300 MG
Description: One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.
Study: NCT01513863

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo applied to affected area once a day for 70 days
Study: NCT02790294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: The routine spine MRI protocol will be utilized, which includes the following sequences: haste localizer, sagittal T1, T2, and short-T1 Inversion Recovery (STIR), axial T2 for lumbar spine or axial gradient echo for cervical and thoracic spine, axial T1, post contrast sagittal and axial T1. All scans will be obtained using a 1.5 Tesla magnet.
Study: NCT01443182

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STAIR
Description: Skills Training in Affective and Interpersonal Regulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAIR
Description: Skills Training in Affective and Interpersonal Regulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MPE
Description: Modified prolonged exposure (MPE)
Study: NCT02855112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose derived mesenchymal stem cell
Description: Allogeneic Adipose derived Mesenchymal Stem cell transplant
Study: NCT00891761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 16 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 20 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV casopitant (placebo)
Description: IV casopitant (placebo) administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV casopitant (active)
Description: Single-dose 90 mg IV casopitant administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: 32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
Study: NCT01525056

Intervention type: RADIATION
Group type: OTHER
Intervention: ct and mri scans
Description: ct and mri scan preradiation and postradiation

Intervention type: RADIATION
Group type: OTHER
Intervention: ct, mri and pet scan
Description: ct, mri and pet scans preradiation and postradiation
Study: NCT01331226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone counseling 1 session
Description: 1 session of telephone counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: written materials only
Description: written materials only
Study: NCT01908543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate 200mg oral tablet
Description: Administration by mouth
Study: NCT02408679

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: One blood sampling will be performed for a serum vitamin D dosage. The volume of blood collected will not exceed 4 ml.

Intervention type: OTHER
Intervention: Predictive questionnaire for vitamin D insufficiency
Description: The questionnaire includes 19 questions concerning the following topics : a) sun exposure, b) living situation, c) eating habits and Vitamin D dietary intakes. In addition, two questions will capture demographic data.
Study: NCT01740258

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT02131311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable, single-use pessary
Study: NCT01479764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: neostigmine, per usual practice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: glycopyrrolate per usual practice
Study: NCT03255889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl Tridecanoate
Description: Glyceryl Tridecanoate (GT) is the triglyceride form of decanoic acid (DA), a C10 fatty acid. GT belongs to the class of medium chain triglycerides (MCT), which has been accepted as a Generally Recognized As Safe food product by FDA. Decanoic acid, also known as capric acid, occurs naturally in coconut oil (8 - 10%) and palm kernel oil (4%).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sunflower oil emulsion of equal calories.
Study: NCT01443182

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMDR
Description: Eye movement desensitization and reprocessing
Study: NCT03775629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polmacoxib and Tramadol combination
Description: Tramadol hydrochloride , Polmacoxib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polmacoxib
Description: Polmacoxib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride
Description: Tramadol hydrochloride (HCl)
Study: NCT03802760

Intervention type: DEVICE
Intervention: Transcranial Doppler (TCD) ultrasound measurement
Description: Non-invasive measurement of cerebral embolic load and blood flow using TCD

Intervention type: DEVICE
Intervention: Transcranial Doppler (TCD) ultrasound measurement
Description: Non-invasive measurement of cerebral embolic load and blood flow using TCD

Intervention type: DEVICE
Intervention: Transcranial Doppler (TCD) ultrasound measurement
Description: Non-invasive measurement of cerebral embolic load and blood flow using TCD
Study: NCT03385564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: subcutaneous injection
Study: NCT01525056

Intervention type: RADIATION
Group type: OTHER
Intervention: ct, mri and pet scans
Description: single arm with ct, mri and pet scans pre and post radiation
Study: NCT01221818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6007
Description: E6007 25mg single dose or matching placebo
Study: NCT02286310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinetic Chain Exercises
Description: Exercises include kinetic chain segments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Exercises
Description: Stretching, strengthening exercises.
Study: NCT02593682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03249974

Intervention type: DEVICE
Intervention: Enlite sensor communicating with Minimed 640G pump
Description: Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
Study: NCT03033082

Intervention type: OTHER
Intervention: Questionnaire sheets
Description: A- Marital satisfaction Index (MSI). Interview (Modified Arabic translation)~B- Sexual Satisfaction Scale:(SSS). The Arabic version of the sexual satisfaction scale was used.~C- International Index of Erectile Function Questionnaire (IIEF-5): For male subjects.~D- The Eysenck Personality Questionnaire (EPQ):~The Arabic version of the EPQ was used.
Study: NCT02213744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT02133820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg 12 hourly capsule - strong pain killer fasted
Study: NCT03043859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pure Prairie Living Program
Description: Education session (n=5) on healthy eating, menu planning and skill building for effective diabetes management
Study: NCT01106664

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-7746
Description: 1mg, 2mg, 4mg, 8mg, 16mg, once daily for multiple-dose study; 4mg at a single dose for food effect study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-7746
Description: 1mg, 2mg, 4mg, 8mg, 16mg once daily for multiple-dose study; 4mg at a single dose for food effect study
Study: NCT03340363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: environmental change
Description: 1. Offer kid-friendly, low-cost recipes in a prominent, high-traffic location.~2. Offer healthy default ingredients (bundled ingredients promoted with recipes).~3. Promote recipe ingredients with prominently displayed signage and images.~4. Promote recipes in multiple locations throughout the store.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: environmental change
Description: 1. Offer kid-friendly, low-cost recipes in a prominent, high-traffic location.~2. Offer healthy default ingredients (bundled ingredients promoted with recipes).~3. Promote recipe ingredients with prominently displayed signage and images.~4. Promote recipes in multiple locations throughout the store.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: messaging
Description: Short, behavioral messages sent to participants via text message or email each week to promote the in-store environmental changes
Study: NCT04644822

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F] PSMA-1007 Injection
Description: a novel \[18F\] PSMA radiotracer that is highly selective for PSMA.
Study: NCT00968786

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Home monitoring
Description: automated measuring devices for patients using at home
Study: NCT03564444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent influenza vaccine
Description: A single dose of bivalent vaccine (10\^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
Study: NCT02133820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 mg 12 hourly capsule - strong pain killer fed
Study: NCT02636426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: In new dosing schedule of sorafenib is investigated in this study: high-dose, pulsatile sorafenib
Study: NCT02562105

Intervention type: PROCEDURE
Intervention: Mechanical ventilation
Description: requiring mechanical ventilation at admission to ICU for one day or more during the study period
Study: NCT03320200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CNS-focused treatment
Description: The CNS-focused treatment will last for 10 weeks, conducted in 60-minute sessions on a weekly basis. In addition, participants in this group will complete a home treatment program for 30 minutes, five times a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care Treatment
Description: The standard physiotherapy group will receive a 10-session treatment program that will include one corticosteroid infiltration provided in the early acute stage followed by a multimodal physiotherapy program including analgesic modalities (e.g. TENS, cryotherapy) and exercise and manual therapy techniques addressing the specific mobility deficits of each patient. This program also include a home treatment based on conventional physiotherapy that involves a training load comparable to that in the CNS-focused group.
Study: NCT00128830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Description: Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleotide reverse transcriptase inhibitors (NRTIs)
Description: Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protease inhibitors (PIs)
Description: Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (ENF)
Description: Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).